NCT05997030 is a NA clinical trial of low intensity focused ultrasound (LIFU) in Alzheimer Disease, sponsored by Ali Rezai.

Who is sponsoring NCT05997030?

NCT05997030 is sponsored by Ali Rezai.

What drugs are being tested in NCT05997030?

Interventions in NCT05997030: low intensity focused ultrasound (LIFU).

What condition does NCT05997030 study?

NCT05997030 studies Alzheimer Disease.

Is NCT05997030 still recruiting?

NCT05997030 is currently recruiting now. Last updated 24 November 2025.

Last reviewed 2025-11-24 · How we verify

NCT05997030

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

Recruiting now NA Last updated 24 November 2025

What this trial tests

NA trial testing low intensity focused ultrasound (LIFU) in Alzheimer Disease in 15 participants. Currently enrolling.

Timeline

12 October 2023

Primary endpoint
30 September 2026

30 September 2026

Quick facts

Lead sponsor	Ali Rezai
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	12 October 2023
Primary completion	30 September 2026
Estimated completion	30 September 2026
Sites	1 location across United States

Drugs / interventions tested

low intensity focused ultrasound (LIFU)

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Ali Rezai

Who can join

Adults 45 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Neurosurgical neuromodulation therapy for psychiatric disorders.
Ranjan M, Mahoney JJ, Rezai AR. · · 2024 · cited 8× · PMID 38688105 · DOI 10.1016/j.neurot.2024.e00366
Low-intensity transcranial ultrasound neuromodulation promotes neuronal regeneration: A new hope for noninvasive treatment of neurodegenerative diseases.
Xia S, He C, Li Y, Li H, et al · · 2026 · cited 1× · PMID 40817729 · DOI 10.4103/nrr.nrr-d-25-00113
Exploring Low‐Intensity Focused‐ultrasound Neuromodulation in Alzheimer's Disease
Rezai A, Teixeira C, Ranjan M, Adams G, et al · · 2025

Verify or expand the search:

Other trials of low intensity focused ultrasound (LIFU)

Trials testing the same drug.

NCT06906211 — Low Intensity Focused Ultrasound for Chronic Pain: High Resolution Targeting of The Human Insula · NA · recruiting
NCT06453109 — Focused Ultrasound for the Complex Patient · NA · recruiting
NCT06405074 — Low Intensity Focused Ultrasound for Tobacco Use Disorder: High Resolution Targeting of the Human Insula · NA · recruiting

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Ali Rezai trials

Trials by the same sponsor.

NCT06763692 — Low Intensity Focused Ultrasound for Parkinson's Disease · NA · not yet recruiting
NCT06485687 — Low Intensity Focused Ultrasound for Binge Eating Disorder · NA · active not recruiting
NCT06218706 — LIFU for Treatment for Refractory Opioid Use Disorder · NA · recruiting
NCT04440891 — Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease · NA · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05997030 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ali Rezai
Last refreshed: 24 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05997030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing